<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401852</url>
  </required_header>
  <id_info>
    <org_study_id>60</org_study_id>
    <nct_id>NCT04401852</nct_id>
  </id_info>
  <brief_title>Magnesium Sulfate for Fetal Neuroprotection</brief_title>
  <official_title>Magnesium Sulphate for Fetal Neuroprotection in Full Term Deliveries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnant women diagnosed to have intrapartum fetal distress (Non reassuring or pathological
      changes according to NICE guidelines 2017) in any of the groups will receive the allocated
      treatment at least 20 minute before the procedure (emergency CS).

      measures to reduce the effect of hypoxia will be applied to all participate through:

        -  The position of the mother will be changed to left lateral position (allow increased
           blood supply).

        -  I.V. fluid bolus (to avoid maternal dehydration).

        -  Oxytocin or cervical ripening agent will be discontinued.

        -  Fetal heart rate monitoring with cardiotocography will be attempted.

        -  If umbilical cord prolapse is noted, elevate the presenting fetal part until preparing
           for emergency operative delivery.

        -  After birth, Apgar score will be used to identify distress newborns that need
           resuscitation.

      The study comprised 200 pregnant women. They were divided into two groups each are 100:

        -  Group A: pregnant women diagnosed to have intrapartum fetal distress who will receive
           MgSO4.

        -  Group B: pregnant women diagnosed to have intrapartum fetal distress who will receive
           placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women diagnosed to have intrapartum fetal distress (Non reassuring or pathological
      changes according to NICE guidelines 2017) in any of the groups will receive the allocated
      treatment at least 20 minute before the procedure (emergency CS).

      measures to reduce the effect of hypoxia will be applied to all participate through:

        -  The position of the mother will be changed to left lateral position (allow increased
           blood supply).

        -  I.V. fluid bolus (to avoid maternal dehydration).

        -  Oxytocin or cervical ripening agent will be discontinued.

        -  Fetal heart rate monitoring with cardiotocography will be attempted.

        -  If umbilical cord prolapse is noted, elevate the presenting fetal part until preparing
           for emergency operative delivery.

        -  After birth, Apgar score will be used to identify distress newborns that need
           resuscitation.

      The study comprised 200 pregnant women. They were divided into two groups each are 100:

        -  Group A: pregnant women diagnosed to have intrapartum fetal distress who will receive
           MgSO4.

        -  Group B: pregnant women diagnosed to have intrapartum fetal distress who will receive
           placebo
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apgar score</measure>
    <time_frame>1 minute after delivery</time_frame>
    <description>Apgar stands for &quot;Appearance, Pulse, Grimace, Activity, and Respiration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fetal Neuroprotection</condition>
  <arm_group>
    <arm_group_label>MgSO4 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will receive an equal volume of isotonic 0.9% saline over 15-20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MgSo4</intervention_name>
    <description>a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.</description>
    <arm_group_label>MgSO4 group</arm_group_label>
    <other_name>magnesium sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <description>equal volume of isotonic 0.9% saline over 15-20 minutes</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women at least 37 week of gestation.

          -  Not more than 35 years old.

          -  Fetal distress (perinatal asphyxia) diagnosed by CTG changes (Non reassuring or
             pathological changes according to NICE guidelines 2017).

          -  Clinical chorioamnionitis.

          -  Prolonged rupture of membranes

        Exclusion Criteria:

          -  Medical disorders such as chronic hypertension, preeclampsia, eclampsia, DM, pulmonary
             hypertension, hepatic coma with risk of renal failure, and any renal, cardiac or
             pulmonary disease.

          -  RH -ve.

          -  Consanguinity.

          -  Preterm labor.

          -  Fetal malpresentation.

          -  Contraindications to the use of Magnesium Sulphate.

          -  Any indication for magnesium Sulphate therapy (seizure prophylaxis or tocolysis).

          -  Myasthenia gravis.

          -  Congenital fetal anomalies.

          -  Fetal growth restriction (birth weight &lt; 10th Percentile for gestational age).

          -  Advanced cervical dilation (8cm).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed maged</last_name>
    <phone>+201005227404</phone>
    <email>ahmedmaged@cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wesam Deeb</last_name>
    <email>wessamdeeb74@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Alainy medical school</name>
      <address>
        <city>Cairo</city>
        <zip>12151</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed M Maged, MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

